Drug Database
AN

anti-tetanus immunoglobulin (Tetglob)

✓ Approved

Bharat Serums and Vaccines Limited · therapeutic agent

What is anti-tetanus immunoglobulin?

anti-tetanus immunoglobulin is a therapeutic agent developed by Bharat Serums and Vaccines Limited. It is approved for therapeutic indications via injectable (others) or intramuscular (im) injection.

Drug Profile

Brand NamesTetglob
CompanyBharat Serums and Vaccines Limited
RouteInjectable (Others), Intramuscular (IM) Injection
StatusApproved
Sources: ClinicalTrials.gov, Bharat Serums and Vaccines Limited

Therapeutic Indications

anti-tetanus immunoglobulin is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Infections and infestationsTetanus✓ Approved

Related Research Articles

PubMedCureus2026-08-30

Lethargy With Reversible Bilateral Basal Ganglia and Substantia Nigra Lesions in Anti-N-Methyl-D-Aspartate Receptor Encephalitis: A Case Report.

Abe Daisuke D, Hidaka Masaoki M, Kumamoto Masaya M, Kanazawa Yuka Y et al.

Anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis is a neuroinflammatory disorder characterized by a broad spectrum of neuropsychiatric symptoms, and the optimal treatment strategy for atypical or refractory cases has not been well established. We report the case of a 26-year-old woman with anti-NMDAR encephalitis associated with an ovarian teratoma who presented with acute psychiatric and neurological manifestations. The patient underwent tumor resection followed by first-line immunotherapies, including corticosteroids, intravenous immunoglobulin, and plasma exchange. Because of persistent neurological symptoms, second-line immunotherapy with cyclophosphamide was initiated, leading to gradual clinical improvement. However, she subsequently developed lethargy and upper-limb tremors, accompanied by bilateral basal ganglia and substantia nigra abnormalities on MRI. Notably, both her clinical symptoms and radiological abnormalities improved following an additional course of cyclophosphamide treatment. This report highlights a rare clinical and radiological manifestation and suggests that additional immunotherapy may be effective for delayed neurological worsening.

PMID 42668959
Read full article →
PubMedExpert review of vaccines2026-08-30

Narrative review of the clinical safety of MenACYW-TT: a quadrivalent meningococcal vaccine conjugated to tetanus toxoid licensed in the US and abroad.

Syrkina Olga O, Bausch-Jurken Mary M, Delgado Arlette A, Jovanovic Jelena J et al.

Routine meningococcal vaccination campaigns have substantially reduced the burden of invasive meningococcal disease in pediatric individuals, leading to relative increases in burden in older age groups. There is a need for safe, effective meningococcal vaccines that can be used across broad age ranges. MenACYW-TT, a quadrivalent tetanus-toxoid-conjugate meningococcal vaccine indicated for individuals aged ≥6 weeks, is one such option. This narrative review summarizes safety data from industry-sponsored pre- and post-licensure clinical trials of MenACYW-TT, including head-to-head studies with active comparators and coadministration studies with routine pediatric vaccines. In >30 trials involving >17,000 participants, MenACYW-TT had a consistent safety profile across all age groups, from infants to older adults. The most frequent side effects were generally mild or moderate and transient; vaccine-related serious adverse events were rare (<0.1%). The safety of MenACYW-TT was comparable to that of other quadrivalent meningococcal conjugate vaccines. Coadministration did not materially affect the safety of MenACYW-TT or routine pediatric vaccines. Immunization remains an essential preventive strategy against the potentially life-threatening and life-altering consequences of invasive meningococcal disease. The favorable benefit-risk profile of MenACYW-TT reinforces the safety of licensed vaccines and can help to counter vaccine hesitancy.

PMID 42668391
Read full article →
PubMed[Rinsho ketsueki] The Japanese journal of clinical hematology2026-08-30

[Intrathecal immunoglobulin administration for refractory viral central nervous system infection after allogeneic hematopoietic stem cell transplantation].

Matsuo Masaaki M, Kusakabe Shinsuke S, Kurashige Ryumei R, Fukushima Kentaro K et al.

Central nervous system (CNS) viral infections after allogeneic hematopoietic stem cell transplantation are associated with poor prognosis and have limited therapeutic options. We report three cases of refractory CNS viral infection treated by combination therapy with antiviral agents and intrathecal immunoglobulin administration. Case 1 involved cytomegalovirus encephalitis, Case 2 varicella zoster virus meningitis, and Case 3 human herpesvirus 6 encephalitis; all were resistant to antiviral agents. Two patients achieved viral DNA negativity in cerebrospinal fluid, and none experienced adverse events related to intrathecal injection. Although no intrathecal immunoglobulin products have been approved for use in Japan, our findings suggest that this treatment may be a viable option in selected refractory cases. Further studies are warranted to clarify the optimal agent, dosage, and schedule.

PMID 42669504
Read full article →
PubMedKidney medicine2026-08-30

NSAID-Induced Acute Interstitial Nephritis Concurrent With IgA Vasculitis: A Case-Based Systematic Review.

Caputo Carmela C, Sessa Concetto C, Serio Vittorio V, Baciga Federica F et al.

Overlap between acute interstitial nephritis (AIN) and glomerulonephritis is uncommon and diagnostically challenging. We present the first pediatric case of clinically diagnosed immunoglobulin A vasculitis nephritis (IgAV-N) concurrent with nonsteroidal anti-inflammatory drug (NSAID)-induced AIN. A 14-year-old boy was hospitalized for recurrent gastroenteritis, purpura, and arthralgia treated with ibuprofen. After 5 days, he developed stage 3 acute kidney injury, subnephrotic proteinuria, hypertension, and oligoanuria. Kidney biopsy showed mild to moderate interstitial inflammation with tubulitis; immunofluorescence was negative for glomerular IgA, with nonspecific tubular C3 staining. After NSAID discontinuation, 10 dialysis sessions, and corticosteroids, kidney function recovered completely within 3 months. To support the clinical lesson highlighted by our case, we conducted a systematic review of biopsy-confirmed AIN-glomerulonephritis overlap. PubMed, Scopus, Web of Science, and Google Scholar were searched for biopsy-confirmed AIN with concurrent glomerulonephritis. Clinical features, etiologies, treatments, and outcomes were extracted. Systematic review identified 8 studies (12 patients). Drug-related AIN predominated (9 of 12), followed by infection (2 of 12) and autoimmune disease (1 of 12). Nephrotic-range proteinuria was described in 6, hematuria in 8, and hypersensitivity findings in 7 of the 12 patients. Complete recovery occurred in 7 and partial recovery in 3 patients, and dialysis was required in 2 of the 12 patients. NSAID-induced AIN concurrent with IgA vasculitis nephritis should be suspected in atypical acute kidney injury.

PMID 42668581
Read full article →
PubMedFood chemistry: X2026-08-30

Proteomic insights into goat milk serum proteins at varying altitudes in China.

Li Zhaomin Z, Wang Shanshan S, Cao Hanwen H, Yan Yingying Y et al.

Using Astral DIA quantitative proteomics, this study characterized serum protein profiles and potential functions of goat milk from different altitude regions. A total of 1446 proteins were identified, with 1268, 1256, and 1346 proteins detected in high-altitude, mid-altitude, and low-altitude samples, respectively. The high-altitude sample contained 34 unique proteins and showed higher abundances of α-lactalbumin, serum albumin, and polymeric immunoglobulin receptor, whereas the low-altitude sample contained 87 unique proteins and higher abundances of several immune-related proteins, including osteopontin, lactoferrin, immunoglobulin, lysozyme, xanthine oxidase, lactoperoxidase, and GLYCAM1. Differentially expressed analysis identified 453, 452, and 113 differential proteins in high-altitude vs. low-altitude, mid-altitude vs. low-altitude, and high-altitude vs. mid-altitude comparisons, respectively. KEGG analysis showed that carbohydrate metabolism was enriched in comparisons involving the low-altitude sample, whereas amino acid metabolism was enriched between high-altitude and mid-altitude samples. Notably, HIF-1 signaling pathway was enriched in the high-altitude sample, suggesting hypoxia-associated proteomic adaptation.

PMID 42668543
Read full article →
PubMedCureus2026-08-30

Rare Presentation of Parsonage-Turner Syndrome Post Tdap Vaccination: A Case Report.

Jervis Matthew M, Dunn-Pirio Anastasie A

Parsonage-Turner Syndrome (PTS) is a rare disorder of the brachial plexus typically characterized by acute shoulder and/or upper extremity pain, followed by muscle weakness. Though the specific etiology of PTS is unclear, numerous associations are cited in the literature, including after routine vaccinations. A previously healthy 22-year-old male developed subacute left upper extremity weakness and numbness < 24 hours following a routine Tdap (tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis) booster vaccination, later evolving into diffuse weakness and sharp shoulder pain. Electromyography (EMG) findings were suggestive of early PTS, and subsequent magnetic resonance imaging (MRI) of the brachial plexus confirmed mild inflammatory changes consistent with brachial plexitis. Over several months, the patient showed clinical improvement with conservative management. This case highlights a rare presentation of post-vaccination PTS, emphasizing the need for early recognition and supportive management. Although rare, clinicians should consider PTS in patients presenting with acute-onset upper extremity pain and weakness following vaccination.

PMID 42668845
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about anti-tetanus immunoglobulin